Citation Impact
Citing Papers
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
2014 Standout
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary
2014 Standout
Highly active antiretroviral therapy and allogeneic CD34+ peripheral blood progenitor cells transplantation in an HIV/HCV coinfected patient with acute myeloid leukemia
2002
Antithrombotic Therapy for Venous Thromboembolic Disease
2008 Standout
Pharmacology and Management of the Vitamin K Antagonists
2008 Standout
Intracellular degradation of secretion defect‐type mutants of antithrombin is inhibited by proteasomal inhibitors
1997 StandoutNobel
Health and economic impact of posttransfusion hepatitis B and cost‐effectiveness analysis of expanded HBV testing protocols of blood donors: a study focused on the European Union
2003
A Clinical Trial of Vena Caval Filters in the Prevention of Pulmonary Embolism in Patients with Proximal Deep-Vein Thrombosis
1998 Standout
Embolic strokes of undetermined source: the case for a new clinical construct
2014 Standout
Association Between CYP2C9 Genetic Variants and Anticoagulation-Related Outcomes During Warfarin Therapy
2002 Standout
Oral Anticoagulant Therapy
2012 Standout
Antithrombotic Therapy for Venous Thromboembolic Disease
1998
Control of fibroblast‐like synoviocyte proliferation by macrophage migration inhibitory factor
2003
Subcutaneous Low-Molecular-Weight Heparin Compared with Continuous Intravenous Heparin in the Treatment of Proximal-Vein Thrombosis
1992 Standout
The Management of Thrombosis in the Antiphospholipid-Antibody Syndrome
1995 Standout
Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura
2001 StandoutNature
Acute Effects of Nicotine Infusion on Platelets in Nicotine Users with Normal and Impaired Renal Function
2000 StandoutNobel
Epidemiological and clinical burden of chronic hepatitis B virus/hepatitis C virus infection. A multicenter Italian study
2003
Coagulation factor abnormalities as possible thrombotic risk factors after Fontan operations
1990
Secretion, γ-carboxylation, and Endoplasmic Reticulum-associated Degradation of Chimeras with Mutually Exchanged Gla Domain Between Human Protein C and Prothrombin
2000 StandoutNobel
Acute hepatitis C: Current status and remaining challenges
2008
Global epidemiology of hepatitis C virus infection
2005 Standout
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
2009 Standout
Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity
2006 Standout
Platelet Activation and Atherothrombosis
2007 Standout
The coagulation cascade: initiation, maintenance, and regulation
1991 Standout
Treatment of von Willebrand's Disease
2004
The Clinical Course of Pulmonary Embolism
1992 Standout
Antithrombotic Therapy for Venous Thromboembolic Disease
1989
Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer
2003 Standout
Initiation of Platelet Adhesion by Arrest onto Fibrinogen or Translocation on von Willebrand Factor
1996 Standout
von Willebrand's disease
1992
Oral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range
2001 Standout
Severe Adverse Cutaneous Reactions to Drugs
1994 Standout
Temporary protein C deficiency associated with cerebral arterial thrombosis in childhood
1988
Small vessel disease: mechanisms and clinical implications
2019 Standout
The Pharmacology and Management of the Vitamin K Antagonists
2004 Standout
Antithrombotic Therapy for Venous Thromboembolic Disease
2001 Standout
Oral Anticoagulant Drugs
1991
Plasma and platelet von Willebrand factor defects in uremia
1988
Long-Term Control of HIV by CCR5 Delta32/Delta32 Stem-Cell Transplantation
2009 Standout
Guidelines for the Early Management of Adults With Ischemic Stroke
2007 Standout
LPS Induces Hypoxia-Inducible Factor 1 Activation in Macrophage-Differentiated Cells in a Reactive Oxygen Species–Dependent Manner
2008 StandoutNobel
2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association
2021 Standout
Guidelines for the Early Management of Patients With Acute Ischemic Stroke
2013 Standout
Comparison of 5-mg and 10-mg Loading Doses in Initiation of Warfarin Therapy
1997
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial
2006 Standout
BIOCHEMISTRY AND GENETICS OF VON WILLEBRAND FACTOR
1998 Standout
Maturation of the hemostatic system during childhood
1992 Standout
Relationship between protein C antigen and anticoagulant activity during oral anticoagulation and in selected disease states.
1986
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
Synthesis and Function of 3-Phosphorylated Inositol Lipids
2001 Standout
Impact, Diagnosis and Treatment of von Willebrand Disease
2000
A Revised Classification of von Willebrand Disease
1994
Inhibitory Anti–Factor V Antibodies Bind to the Factor V C2 Domain and Are Associated With Hemorrhagic Manifestations
1998
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2019 Standout
Enhanced proteolysis of plasma von Willebrand factor in thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome
1989
Guide to anticoagulant therapy. Part 2: Oral anticoagulants. American Heart Association.
1994
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons
2019 Standout
Substructure of human von Willebrand factor.
1985
MIF Signal Transduction Initiated by Binding to CD74
2003 Standout
Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack
2006 Standout
Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention
2009 Standout
ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease
2006 Standout
Subunit composition of plasma von Willebrand factor. Cleavage is present in normal individuals, increased in IIA and IIB von Willebrand disease, but minimal in variants with aberrant structure of individual oligomers (types IIC, IID, and IIE).
1986
Efficacy of Antiplatelet Therapy in Secondary Prevention Following Lacunar Stroke
2015
The relationship between inhibition of vitamin K1 2,3‐epoxide reductase and reduction of clotting factor activity with warfarin.
1988
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
Cellular Basis for Protein C Deficiency Caused by a Single Amino Acid Substitution at Argl5 in the -Carboxyglutamic Acid Domain
1996
EASL Recommendations on Treatment of Hepatitis C 2018
2018 Standout
Warfarin and Heparin-Induced Skin Necrosis and the Purple Toe Syndrome: Infrequent Complications of Anticoagulant Treatment
1997
von Willebrand factor and von Willebrand disease [published erratum appears in Blood 1988 Mar;71(3):830]
1987
Coordinate Activation of HIF-1 and NF-κB DNA Binding and COX-2 and VEGF Expression in Retinal Cells by Hypoxia
2003
2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease
2008 Standout
Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack
2010 Standout
Epidemiological investigation of the prevalence of von Willebrand's disease
1987
Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon.
1987 Standout
Antithrombotic Therapy for Venous Thromboembolic Disease
1995
A new von Willebrand factor (vWF) defect in a patient with factor VIII (FVIII) deficiency but with normal levels and multimeric patterns of both plasma and platelet vWF. Characterization of abnormal vWF/FVIII interaction
1990
Works of S. Solinas being referenced
An estimate of the current risk of transmitting blood‐borne infections through blood transfusion in Italy
2002
THE ROLE OF HEPATITIS C AND B VIRUS INFECTIONS AS RISK FACTORS FOR SEVERE LIVER COMPLICATIONS FOLLOWING ALLOGENEIC BMT: A PROSPECTIVE STUDY BY THE INFECTIOUS DISEASE WORKING PARTY OF THE EUROPEAN BLOOD AND MARROW TRANSPLANTATION GROUP1
1999
A variant of von Willebrand's disease characterized by recessive inheritance and missing triplet structure of von Willebrand factor multimers
1983
Heterogeneity of type I von Willebrand disease: evidence for a subgroup with an abnormal von Willebrand factor
1985
Evaluation of the effectiveness of DDAVP in surgery and in bleeding episodes in haemophilia and von Willebrand's disease. A study on 43 patients
2008
Inhibitor to factor V in severe factor V congenital deficiency. A case report.
1985
Decrease in protein C antigen and formation of an abnormal protein soon after starting oral anticoagulant therapy
1984
Plasma histamine levels during plasmapheresis: difficult interpretation of adverse reactions to plasma substitutes
2001
Decrease in protein C antigen and formation of an abnormal protein soon after starting oral anticoagulant therapy
1984